Background. The development of novel artemisinin-combination therapies suitable for the treatment of pediatric patients suffering from malaria is a research priority. The aim of this study was to investigate a novel fixed-dose pyronaridine-artesunate combination for the treatment of uncomplicated falciparum malaria in Gabonese patients 2-14 years old.
(less than $1 per adult-treatment course), long shelf life, and an easy dosing regimen of 1 daily dose over 3 days [10] .
Pyronaridine, a Mannich base 1-aza-acridine structurally related to mepacrine, one of the earliest synthetic antimalarial drugs, was first developed in China Ͼ30 years ago [11] . It has been used successfully as antimalarial monotherapy in eastern Asia and currently is marketed, in both oral and injectable formulations, in China [12] . Available data on pediatric patients in Africa indicate that pyronaridine is effective in cases that are resistant to chloroquine [13] . There is evidence that resistance to pyronaridine may emerge when the latter is used as monotherapy on a large scale [14] . Therefore, the rationale for treatment with a fixed-dose pyronaridine-artesunate combination is to achieve both rapid symptomatic relief and high cure rates and to delay the development of drug resistance.
Data from phase I and phase II studies of adults have demonstrated that the pyronaridine-artesunate combination has a good safety profile. Because children are the population primarily affected by malaria, the present study investigated a population of pediatric patients to determine the most appropriate dose of pyronaridine-artesunate, in 3 different tablet formulations and in a novel granule formulation. The main objectives were to determine (1) the pharmacokinetics of the 3 fixed-dose pyronaridine-artesunate tablet coformulations, (2) the relative bioavailability of the granule coformulation, and (3) the safety and tolerability of all dose formulations.
MATERIALS AND METHODS

Study design and outcome measures. The study was designed
as an open-label sequential dose-escalation study. Tablet coformulations of 3 different fixed-dose pyronaridine-artesunate combinations-with pyronaridine tetraphosphate:artesunate ratios of 6:2, 9:3, and 12:4 mg/kg-were evaluated. The primary outcome measures were safety, tolerability, and pharmacokinetics; pharmacodynamics was a secondary outcome measure and was classified according to World Health Organization recommendations [15] . The polymerase chain reaction (PCR)-corrected adequate clinical and parasitological response (ACPR) rate at day 28 served as the primary efficacy end point in perprotocol (PP) analysis and as the secondary efficacy outcome in modified intention-to-treat (ITT) analysis. Each of the 4 cohorts included 15 patients; this sample size was chosen in this descriptive study in order to obtain, for each dose level, at least 12 patients who would be evaluable in terms of the primary outcome measures.
After treatment with the 3 tablet coformulations of pyronaridineartesunate had been concluded, a protocol extension was implemented to evaluate the granule coformulation. This drug formulation was specifically developed for the treatment of very young children, to increase the acceptability of the drug; on the basis of previous results, the 9:3-mg/kg pyronaridine:artesunate dose was evaluated in 15 patients. The primary aim of this protocol extension was the assessment of the relative bioavailability of the granule coformulation versus that of the tablet coformulations.
Study area and enrollment. The study was conducted during June-December 2006 at the Medical Research Unit of the Albert Schweitzer Hospital in Lambaréné, Gabon [16] . P. falciparum is transmitted perennially and shows both 100% resistance to chloroquine and reduced sensitivity to sulfadoxinepyrimethamine [17 21] .
Patients suffering from uncomplicated P. falciparum malaria were invited to participate in the study if the following inclusion criteria were met: P. falciparum monoinfection (parasitemia, 1000 -200,000 parasites/L blood), age 2-14 years, body weight 10 -40 kg, absence of pregnancy and of severe malnutrition, and ability to tolerate oral medication. Exclusion criteria were signs or symptoms of severe malaria or severe diarrhea, evidence of significant disorders, other febrile conditions, hypersensitivity to the study drugs, intake of antimalarial drugs during the preceding 2 weeks, liver function-test results that were Ͼ3 times above normal levels, and significant renal impairment (plasma/ blood creatinine level 2 mg/dL).
Written informed consent was obtained from parents or guardians, and, when appropriate, the assent of the pediatric patients was obtained. The study was approved by the Ethics Committee of the International Foundation for the Albert Schweitzer Hospital in Lambaréné.
Study drugs and study flow. At the first visit, the patient's medical history was recorded, a physical examination was performed, and hematological, biochemical, and parasitological characteristics were determined. The pyronaridine-artesunate combination (Pyramax; Shin Poong Pharmaceutical) was first administered at the lowest level, 6:2 mg/kg body weight, and, after a Safety Oversight Group had reviewed the patient's clinical and laboratory data, the dose was increased to 9:3 and then to 12:4 mg/kg; this study design allowed for assessment of the safety and tolerability of the pyronaridine-artesunate combination before the dose was increased. The tablet coformulations contained 48 mg of pyronaridine tetraphosphate (the dosing regimen was based on pyronaridine salt; 100 mg of salt is equivalent to 56.93 mg of free-base pyronaridine) and 16 mg of artesunate, for group A; 72 mg of pyronaridine tetraphosphate and 24 mg of artesunate, for group B; and 96 mg of pyronaridine tetraphosphate and 32 mg of artesunate, for group C. The granule coformulation used for group D was administered in a sachet that contained 60 mg of pyronaridine tetraphosphate and 20 mg of artesunate in taste-masked granules. All of the drug formulations were administered with liquid once daily for 3 days. Patients were hospitalized during the treatment period, and follow-up visits were scheduled until day 42.
Pharmacokinetics. For pharmacokinetic analysis of pyronaridine, artesunate, and the principal active metabolite dihydroartemisinin, 1 mL of blood was drawn at the following times: before administration of the study drug; at 0.25 (for artesunate or dihydroartemisinin only), 0.5, 1.0, 1.5, 2.5, 4.0, 8.0, and 12.0 h after intake of the first drug; before administration of the second drug; before administration of the third drug; 24 h after administration of the third drug (for pyronaridine only); at 168 (for pyronaridine only), 336 (for pyronaridine only), and 504 (for pyronaridine only) h after initiation of treatment; and if parasitemia reappeared (for pyronaridine only). Plasma concentrations of artesunate and of dihydroartemisinin were determined by liquid-chromatography mass-spectrometry analysis, and blood concentrations of pyronaridine were measured in whole-blood samples by liquid chromatography, as described elsewhere (Ͻ11.1% relative SD of quality-control samples) [22, 23] .
Laboratory analysis. Results of electrocardiography (CT110 CardioConcept; SECA) were interpreted by both a study physician on site and an independent reviewer at a different location.
A sequential approach to distinguishing between recrudescent and newly acquired infections was performed by analysis of merozoite surface antigen (MSA)-2 length polymorphisms and gene-product sequencing. DNA was extracted from blood spots (FTA Classic Card; Whatman International) of anonymized samples (QIAmp DNA extraction; Qiagen). The P. falciparum MSA-2 gene was amplified by use of a family-specific nested- PCR protocol, and length polymorphisms of PCR products were analyzed by electrophoresis (Biometra Uno thermal cycler) [24] . When at least 1 PCR product from 1 family was of similar size at inclusion and at day of reappearance, the PCR products were sequenced by use of forward and backward PCR primers (BigDye chemistry 3100; Applied Biosystems).
Recrudescence was considered to have occurred if, at baseline and at the time of reappearing parasitemia, there were at least 2 amplified DNA fragments of the same size and at least 2 gene products with identical sequences; reinfection was considered to have occurred if at least 1 of these 2 conditions was not met. When PCR and sequence analysis could not determine the status, recrudescence was assumed to have occurred.
Statistical analysis. The accuracy of data was checked on the basis of a predefined data-validation plan. Standard descriptive statistics were used for quantitative variables, and rates and proportions were used for categorical variables (SAS version 8.2). ACPR was summarized by use of exact 95% PearsonClopper confidence intervals. Parasite-clearance times were analyzed by Kaplan-Meier survival analysis. Two populations were defined for statistical analysis: a modified ITT population (all patients received at least 1 dose of study medication) and a PP population (all patients received a full course of treatment; their PCR-corrected ACPR status at day 28 was known, and there were no major protocol violations). ITT analysis was performed to determine safety and tolerability, and PP analysis was performed to define the primary efficacy outcome.
Pharmacokinetic parameters were computed by noncompartmental analysis (WinNonlin Professional model 200, version 5.0; Pharsight). Peak plasma/blood concentrations were determined without interpolation, and the area under the curve (AUC) was computed by use of the linear trapezoidal rule. The log-linear proportion (at least 3 plasma concentrations for artesunate and for dihydroartemisinin and at least 4 blood concentrations for pyronaridine) was used to determine the terminalphase hybrid constant z . The volume of distribution was calculated as follows: dose/( z ϫ AUC 0-ϱ ). Total-body clearance for extravascular administration was calculated by dividing the dose by AUC 0 -ϱ . Pairwise comparisons of untransformed pharmacokinetic parameters were performed by use of 2-sided t tests, with P Ͻ .05 as the level of significance and with no adjustment for multiple testing.
RESULTS
A total of 60 patients were enrolled in this clinical study during June-December 2006; 15 patients were sequentially assigned to each dose level, and the baseline characteristics of the 4 groups were comparable (table 1). All patients were included in the ITT analysis, except for 1 patient in group A who was unable to tolerate oral medication and therefore was removed from the study (20) 3 (20) 1 (7) Headache 5 (36) 1 (7) 2 (13) 1 (7) Fatigue or pyrexia 2 (14) 2 (23) 1 (7) 2 (13) Cough 2 (14) 1 (7) 2 (13) 1 (7) Splenomegaly or hepatomegaly 1 (7) 2 (13) 3 (20) 1 (7) Anorexia 2 (14) 0 (0) 1 (7) 1 (7) Any possibly drug-related AE Gastrointestinal disorders 3 (21) 2 (13) 2 (13) 1 (7) Fatigue or pyrexia 1 (7) 1 (7) 0 (0) 1 (7) Splenomegaly or hepatomegaly 0 (0) 1 (7) 2 (13) 0 (0)
Hyperhidrosis 0 (0) 0 (0) 1 ( population. During the course of the study, 11 patients were excluded from the PP analysis because they either required antimalarial treatment of reappearing parasitemia during follow-up (n ϭ 4), developed P. ovale infection (n ϭ 1), vomited redosed study medications (n ϭ 2), withdrew consent (n ϭ 1), ingested prohibited medication (n ϭ 1), and were lost to followup (n ϭ 2); these patients were classified, in ITT analysis, as treatment failures. The disposition of the patients during the course of this clinical trial is shown in figure 1 . Safety, tolerability, and evolution of laboratory data. In the 4 treatment groups, 73%-93% of patients experienced at least 1 adverse event (AE) during the course of this study (table  2) , and one-third (20%-36%) of these cases were judged as being at least possibly related to the study drugs. The majority of AEs that were related to the study drugs were gastrointestinal disorders, including vomiting (n ϭ 4), abdominal pain (n ϭ 4), diarrhea (n ϭ 1), and nausea (n ϭ 1); other AEs that were at least possibly related to the study drugs were rare. No abnormal electrocardiographic result associated with the study drugs occurred in this clinical trial.
All AEs in the present study were of mild or moderate intensity; none was severe or life-threatening. Overall, there was no observable increase in the rate or severity of AEs during the doseescalation procedure. The 2 serious AEs that did occur during the course of the present study-specifically, a soft-tissue infection of the right thumb, which necessitated surgical treatment, and hospitalization for observation of an unspecified febrile episode with abdominal pain and no evidence of parasitemia during the third week of follow up (both of these AEs occurred in group A)-were not related to the study drugs.
Hematological analysis, biochemical analysis, and urinalysis were performed for all patients, at enrollment and on days 3 and 7 (table 3) . There was a modest decrease in median hemoglobin levels during the first 72 h of treatment, with complete recovery to initial levels by day 7. In 1 patient, there was a clinically significant, 2.5-g/dl decrease in hemoglobin during the first 24 h, but, without further intervention, the hemoglobin level subsequently increased until, by day 7, it was 7.7 g/dL, which exceeded the baseline value. A general rise in platelet count and eosinophil count was noted during the study. Abnormalities revealed by urinalysis were caused by concomitant Schistosoma haematobium infections. There were no clinically significant changes in the biochemical parameters during the course of the study (table  3) .
Pharmacokinetics. Pharmacokinetic characteristics of pyronaridine, artesunate, and dihydroartemisinin were evaluated in all patients (table 4). For artesunate, both the mean maximum plasma concentration (C max ) and the mean AUC 0 -ϱ increased in a dose-dependent manner, from 93 ng/mL to 287 ng/mL/h and from 104 to 232 ng/mL/h, respectively; the time to C max was 0.5-1.0 h, and the terminal half-life was 0.5-1.2 h. Dihydroartemisinin, the major active metabolite of artesunate, showed a linear increase both in C max , from 479 to 1186 ng/mL, and in AUC, from 1055 to 2961 ng/mL/h; the time to C max was 1.3-1.7 h after administration. Dihydroartemisinin showed a relatively short half-life of 0.9 -1.2 h. The blood concentration of pyronaridine also increased in a dose-dependent pattern: both C max and AUC rose, from 86 ng/mL to 339 ng/mL and from 17,623 to 35,360 ng/mL/h, respectively; the time to C max was 2.4 -3.2 h, and the elimination half-life was 6.6 -9.0 days (table 4). The pharmacokinetic parameters of the granule coformulation were compared with those of the tablet formulation of the same dose (i.e., the pyronaridine:artesunate ratio of 9:3 mg/kg); there were no statistically significant differences, except for a higher C max (168 ng/mL vs. 119 ng/mL [P Ͻ .05]; table 4) of pyronaridine in the patients receiving the granule coformulation.
Efficacy. All patients showed a satisfactory initial response to the study drugs, and no early treatment failure was observed during the course of the trial. A total of 14 patients-4, 6, 2, and 2 in groups A, B, C, and D, respectively-had reappearing P. falciparum parasitemia during follow-up, and 1 patient in group A had P. ovale infection at day 39. The earliest reappearance of P. falciparum infection was observed at day 21, whereas all other reappearing parasitemias occurred after day 28.
By day 28, 53 patients had reached the primary efficacy end point in the PP analysis (table 5) , and all evaluable patients had experienced ACPR (100% cure rate [95% confidence interval 93%-100%] when data from all groups are pooled). Two patients were classified, on the basis of genotyping, as true treatment failures (on days 35 and 36 in the 9:3 mg/kg tablet and granule coformulation groups, respectively). The PCRcorrected efficacy at day 42 was 89%-100% in the 4 groups. Parasite-clearance times were remarkably short, with a median of 16, 16, 8 , and 8 h in groups A, B, C, and D, respectively. There was thus a statistically significant trend toward faster parasite clearance in the higher-dose groups (P Ͻ .05 for group A vs. group C, by Tukey-Kramer honestly significant difference test). The results of the ITT analysis are provided in table 5.
DISCUSSION
Young children in sub-Saharan Africa suffer disproportionately from malaria-related morbidity and mortality and therefore should be the primary target population for treatment with novel antimalarial regimens [25, 26] . Although the introduction of artemisinin-combination therapies in most regions where malaria is endemic has led to sustained and unparalleled high cure rates, there is a lack of suitable pediatric drug formulations [1, 27] . Therefore, therapeutic management of patients who are most in need of effective treatment is often suboptimal, and the development of pediatric drug formulations is a research priority.
In the present study, pyronaridine-artesunate therapy had a good tolerability profile at all doses used. Most AEs were of mild or moderate intensity, with gastrointestinal symptoms occur- ring most frequently. Most important, the treatment produced no dose-dependent increase in AEs and no dose-limiting side effects. Given the inherent difficulty in differentiating between side effects of the study drugs and symptoms of malaria in uncontrolled phase II studies, the tolerability of pyronaridineartesunate will be fully established only by larger randomized controlled trials and postmarketing surveillance. Despite these limitations of the present study and the relatively modest number of patients that it considered, it is reassuring that no safety concerns occurred during the dose-escalation procedure. In the present study, the standard pharmacokinetic parameters of artesunate were comparable with previous findings in adults [28, 29] and children [30, 31] , despite methodological and dose differences. Artesunate showed a rapid biotransformation to dihydroartemisinin, with overall C max levels that were lower than those observed for its metabolite dihydroartemisinin. Interestingly, artemisinin derivatives generally show marked interpatient variability, with an exceptionally wide range of C max levels [31, 32] . However, in the present study, there was no obvious relationship between variation in C max levels and pharmacodynamic efficacy.
Similar to what previously had been reported on pyronaridine treatment in adults, the elimination half-life in the pediatric population in the present study was in the range of 1 week [23] . Antimalarial drugs with a long half-life may be particularly vulnerable for development of drug-resistant P. falciparum isolates [1] . Given the comparatively shorter half-life of pyronaridine, compared with that of combination partners such as piperaquine, treatment with pyronaridine-artesunate may therefore prove to be particularly useful in regions where malaria has a high rate of transmission.
By day 28, the cure rates were 100% in the PP analysis, for all dose levels and for both the tablet and granule coformulations; however, they showed a dose-dependent increase in the ITT analysis. There was no indication that the pharmacokinetic parameters in the 2 patients who were classified as treatment failures were significantly different from those in the other patients. Similarly, despite a dosedependent increase in both the C max and the AUC of the active metabolites, the different doses showed no difference in PCRcorrected cure rates. Although not designed as a dose-finding study to detect efficacy differences between groups, the present clinical trial found that pyronaridine-artesunate therapy has high intrinsic activity in central Africa.
A major aim of this drug-development program is to make an appropriate and registered pediatric drug formulation available for the treatment of young children. Therefore, a granule coformulation of pyronaridine-artesunate was developed, which considerably facilitated drug intake by young children. The tolerability, safety, and efficacy of this coformulation were similar to those of the 3 tablet coformulations, and, except for a trend toward higher C max levels of pyronaridine, all relevant pharmacokinetic parameters showed that the relative bioavailability of the granule coformulation was comparable to those of the tablet coformulations. Despite its statistical significance in unadjusted analysis, the granule coformulation's trend toward higher C max levels of pyronaridine is unlikely to cause difficulties, given that, even at the higher C max levels seen in the group treated with the 12:4 mg/kg tablet-coformulation, the study drug showed a good tolerability profile. In light of the favorable clinical and pharmacokinetic results observed for the granule coformulation, it has the potential, through improved acceptability and compliance by patients, to significantly ameliorate the management of patients in regions where malaria is endemic. Terminal half-life, h a 9.0 Ϯ 2.5 7.0 Ϯ 1.9 6.6 Ϯ 2.0 6.7 Ϯ 1.8
NOTE.
Data are mean Ϯ SD, except in the case of the no. of patients tested. AUC, area under the curve; C max , mean maximum plasma/blood concentration. a n ϭ 12 for group A, n ϭ 12 for group B, n ϭ 10 for group C, and n ϭ 13 for group D. b Three patients with a new infection on day 28 were considered to be cured at day 28 and were not taken into account for the day-42 analysis. One patient was not taken into account for the day-42 analysis because he was lost to follow-up on day 35.
c One patient did not come for the day-28 visit but returned for further follow-up visits up to day 42; this patient was classified as "treatment failure" for the day-28 analysis and as "cured" for the day-42 analysis.
In summary, this pediatric phase II study has demonstrated that, at all doses considered, pyronaridine-artesunate combination therapy has a good tolerability and safety profile in 2-14-year-old patients in Gabon. Given the high efficacy of this drug combination, both the tablet coformulations and the granule coformulation warrant further development.
